Principal Investigator for Phase 3 Studies
- Diabetes in Indians – A Scale for Holistic Approach, DISHA Investigator-initiated ongoing trial to design a scale specific to India, 2025
- Impact of Soleus Push-Ups (SPU) on Glycemic and Lipid Parameters Investigator-initiated ongoing multi-centre, prospective study on pre-diabetes & Type 2 Diabetes, 2025
- Impact of Advanced Metabolic System TM Formulation on Weight, Metabolic Markers, and Digestive Function in Obese Adults A Randomized Controlled Trial, 2024, Goodbug, Completed.
- Safety of Fixed-Dose Combination of Dapagliflozin & Saxagliptin Phase IV | Sponsor: AstraZeneca, 2020
- LIRA-PRIME: Efficacy of Liraglutide as Add-On to Metformin Phase III | Sponsor: Novo Nordisk, 2018-19
- A Safety and Efficacy of Exenatide Injection in Subjects with Type 2 Diabetes Mellitus: A randomized, double blind, placebo-controlled, parallel group multi-centric, 24-week trial Phase III | Sponsor: Sun Pharma, 2018 –19
- A randomized open label, non-inferiority, comparative, multicentric study between beclomethasone dipropionate MDI VS Clenil in a 12-week treatment period of adult patients with mild to moderate persistent Asthma. Phase III | Sponsor: Glenmark, 2012-13
- Multicentric, Comparative Controlled, Open Labelled Randomized, Parallel-Group, Phase III Study to Evaluate the Safety and Efficacy of FDC Containing Rosuvastatin Calcium and Ezetimibe in Dyslipidemia Patients Phase III | Sponsor: Biocon, 2011-12
- A multinational, multi-centre, post-authorization, prospective observational cohort study to assess the profile of Vildagliptin and the fixed-dose combination of Vildagliptin/Metformin relative to comparator oral antidiabetic drugs in patients with type 2 Diabetes in a real-world setting – EDGE Phase III | Sponsor: Novartis, 2011-12
- A multi-centre, randomized, double-blind placebo controlled study to evaluate the efficacy and safety of 24 weeks treatment with vildagliptin 50 mg bid as add-on therapy to metformin plus glimepiride in patients with type2 diabetes. Phase III | Sponsor: Novartis, 2011-12
Principal Investigator for Phase 4 Studies at Clinisearch
- Indian Heart Study: Largest National Study on Blood Pressure by Heart Care Foundation of India, August 2018
- LEADD Registry: Learning with Experts to Advance Diabetes Dyslipidemia Management Program A Pan-India Registry, June 2018
- IP - Indian Phenotype Registry: A Prospective Data Registry Astra Zeneca Pharma Ltd. January 2018
- LANDMARCK Study – A Longitudinal Nationwide Study on Management and Real-World Outcomes of Diabetes in India. July 2017. Sanofi India
- Usage of Dapagliflozin - A Sodium Glucose Co-Transporter Inhibitor, in the Management of Type-2 Diabetes Mellitus: A Real-World Evidence Study in Indian Patients (FOREFRONT) April 2017. Astra Zenica Pharma
- Scientific Guidance in Understanding & Representing the AGI Combinations in Glycemic Pentad Abbot, January 2017
- IDMPS Wave 7 for Sanofi Diabetes April 2016
- JADE – A Landscape program by Asia Diabetes Foundation MSD 2015
- A multi-centric, cross-sectional, non-interventional, observational study to determine the lipid control in High-Risk Dyslipidemia Patients Treated with Lipid-Lowering Therapy in Indian Population Abbot 2014
- A Multi-Centric, Cross-Sectional, Non-Interventional, Observational Study to Determine The Vitamin D Levels Diabetes Patients and Their Correlation with Glycemic Control Abbot 2014
- Trials on Insulin and Liraglutide –Hypoglycemia Awareness Tool Improve Control 2012, Idea 2, Improve, Insutreat, Lead (Novo Nordisk), & Basal Bolus (Sanofi Aventis) 2013
- STAR Registry – Stable Angina Registry (Medtronic) IDMPS - International Diabetes Management Practice Study (Sanofi Aventis) 2012
- OBSTACLE Hypoglycemia Study MSD, 2009-10
- EDGE, AHEAD Novartis. 2010 – 11
- ‘Heart Asia Registry’, SUAP Registry, I – Control Projects in the Management of Hypertension. 2007-08
- SOTS – Sympathetic Over Activity in Young Hypertensives AstraZeneca. 2008-09
Co-Investigator for Trials at Lotus Diagnostic Centre
- A randomized multi-centre, double blind placebo-controlled study of effects of Aleglitazar on cardiovascular outcome in adult subjects with type 2 diabetes Phase III | Sponsor: Roche, 2010
- A randomized multi-centre comparing the efficacy of NN5401 – 3590 as an add on therapy for poorly controlled diabetes subjects for evaluating the safety and efficacy of the study drug. Phase III | Sponsor: Novo Nordisk, Sponsor Audited, 2010
- A Randomized multi-centre, double blind placebo-controlled study of effects of JNJ 2843174 on cardiovascular outcome in adult subjects with Type 2 Diabetes: Canagliflozin Cardiovascular Assessment Study. Phase III | Sponsor: JNJ, 2010
- Randomized, double-blind, placebo-controlled, parallel group study to determine whether, in patients with type 2 diabetes at high risk of cardiovascular and renal events, aliskiren on top of conventional treatment reduces cardiovascular and renal morbidity and mortality. Phase III | Sponsor: Novartis, 2007
- 24-weeks national multi-centric, parallel group, double-blind placebo-controlled phase 3B study in India to evaluate and safety of Saxagliptin in adult patients with inadequate Glycemic control on diet and exercise. Phase III | Sponsor: Astra Zeneca, 2009
- Target glycemic control and the incidence of documented symptomatic hypoglycemia in insulin Naïve subjects with type 2 Diabetes failing on oral hypoglycemic Agent(s) and treated with Lantus (Insulin Glargine) or Levemir (Insulin Detemir): Multi-centre, multinational, randomized, Open-Label, Comparative, Parallel-group study. Phase III | Sponsor: Sanofi Aventis, 2008
- Randomized, double–blind, placebo-and active comparator-controlled, parallel-group study of the efficacy and safety of Rivoglitazone as Monotherapy treatment of Type 2 Diabetes Mellitus. Phase III | Sponsor: Novartis, 2007, Daiichi Sankyo
Audit Experience
- Audited by CLINIAUDIT, USA, at Lotus Diagnostic Centre for a Phase III diabetes trial
- Three trials (internal/sponsor audits) at Lotus Diagnostic Centre
- One trial (internal/sponsor audit) at Clinisearch as the Primary Investigator